Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.
Carla CasuloArmando SantoroGuillaume CartronKiyoshi AndoJavier MunozSteven Le GouillKoji IzutsuSimon RulePieternella LugtenburgJia RuanLuca ArcainiMarie-Laure CasadebaigBrian FoxNurgul KilavuzNils RettbyJustine Dell'AringaLilia TaningcoRichard DelarueMyron CzuczmanThomas E WitzigPublished in: Cancer reports (Hoboken, N.J.) (2022)
Durvalumab as monotherapy or in combination is tolerable but requires close monitoring. The high rate of TEAEs during this study may reflect on the difficulty in combining durvalumab with full doses of other agents. Durvalumab alone or in combination appeared to add limited benefit to therapy.